No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy

Direct-acting antiviral (DAA)-based therapy is the new standard treatment for chronic hepatitis C virus (HCV) infection. However, protease inhibitor (PI)-resistant viral variants have been often described. This study aimed to examine HCV-NS3 protease variants at baseline and at 4 weeks under triple...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BBA Clin
Hlavní autoři: Hoffmann, Luísa, Faffe, Débora Souza, Lima, Jennifer Fróes Cruz, Capitanio, Thayanna Araujo, Cabral, Bianca Catarina Azeredo, Ürményi, Turán Péter, Coelho, Henrique Sergio Moraes, Rondinelli, Edson, Villela-Nogueira, Cristiane Alves, Silva, Rosane
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2015
Témata:
Regular Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4661554/
https://ncbi.nlm.nih.gov/pubmed/26674563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbacli.2015.01.004
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky